Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06889649
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Prospective Study on the Efficacy and Safety of Stereotactic Ablative Body Radiotherapy Combined with Axitinib and Toripalimab in Recurrent or Metastatic Renal Cell Carcinoma
Sponsor: Peking University First Hospital
Interventions
Axitinib (VEGF-TKI) Stereotactic Ablative Body Radiotherapy (SABR) TORIPALIMAB INJECTION(JS001 )
Updated 1 time since 2025 Last updated: Mar 19, 2025 Started: Jan 1, 2019 Primary completion: Feb 28, 2027 Completion: Feb 20, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06889649, this PHASE2 trial focuses on Immunotherapy and Radiation Therapy and remains actively recruiting participants. Sponsored by Peking University First Hospital, it has been updated 1 time since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Peking University First Hospital
Data source: Peking University First Hospital
For direct contact, visit the study record on ClinicalTrials.gov .